Pramodini B Kale-Pradhan1, Christopher Giuliano1, Annelise Jongekrijg1, Michael J Rybak2. 1. Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Science, Ascension St. John Hospital, Wayne State University, Detroit, Michigan, USA. 2. Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy & Health Sciences, Wayne State University, Detroit, Michigan, USA.
Abstract
INTRODUCTION: Observational and randomized controlled trials of the combination of vancomycin or daptomycin with a beta-lactam (BL) in patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteremia have shown conflicting results on patient outcomes. OBJECTIVES: The primary purpose of this meta-analysis was to compare clinical failure with the combination of vancomycin or daptomycin with a BL versus vancomycin or daptomycin monotherapy in MRSA bacteremia or endocarditis. METHODS: A systematic literature search of PubMed, Embase, CINAHL, and meeting proceedings was conducted from inception through February 11, 2020, to identify relevant studies. The primary outcome was clinical failure and secondary outcomes were mortality, nephrotoxicity, and bacteremia. The meta-analysis was performed using Comprehensive Meta Analysis (version 3.0) with a random effects model. Outcomes were reported as odds ratios (ORs) with corresponding 95% confidence intervals (CIs). RESULTS: Nine studies of 1636 patients receiving vancomycin or daptomycin monotherapy versus the combination of vancomycin or daptomycin plus BL for MRSA bacteremia were included. Results showed combination therapy was associated with significantly lower clinical failure rates (OR 0.56, 95% CI 0.39-0.79, I2 = 26.22%, p=0.001). Improvement in clinical failure was driven by lower rates of bacteremia relapse and persistence. However, no difference was seen with mortality. CONCLUSIONS: Combination therapy with vancomycin or daptomycin plus BL for MRSA bacteremia showed lower clinical failure rates, however, no significant difference was seen in mortality.
INTRODUCTION: Observational and randomized controlled trials of the combination of vancomycin or daptomycin with a beta-lactam (BL) in patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteremia have shown conflicting results on patient outcomes. OBJECTIVES: The primary purpose of this meta-analysis was to compare clinical failure with the combination of vancomycin or daptomycin with a BL versus vancomycin or daptomycin monotherapy in MRSA bacteremia or endocarditis. METHODS: A systematic literature search of PubMed, Embase, CINAHL, and meeting proceedings was conducted from inception through February 11, 2020, to identify relevant studies. The primary outcome was clinical failure and secondary outcomes were mortality, nephrotoxicity, and bacteremia. The meta-analysis was performed using Comprehensive Meta Analysis (version 3.0) with a random effects model. Outcomes were reported as odds ratios (ORs) with corresponding 95% confidence intervals (CIs). RESULTS: Nine studies of 1636 patients receiving vancomycin or daptomycin monotherapy versus the combination of vancomycin or daptomycin plus BL for MRSA bacteremia were included. Results showed combination therapy was associated with significantly lower clinical failure rates (OR 0.56, 95% CI 0.39-0.79, I2 = 26.22%, p=0.001). Improvement in clinical failure was driven by lower rates of bacteremia relapse and persistence. However, no difference was seen with mortality. CONCLUSIONS: Combination therapy with vancomycin or daptomycin plus BL for MRSA bacteremia showed lower clinical failure rates, however, no significant difference was seen in mortality.
Authors: Miguel A Chavez; Satish Munigala; Carey-Ann D Burnham; Melanie L Yarbrough; David K Warren Journal: J Clin Microbiol Date: 2022-03-16 Impact factor: 11.677
Authors: Daniele Roberto Giacobbe; Silvia Dettori; Silvia Corcione; Antonio Vena; Chiara Sepulcri; Alberto Enrico Maraolo; Francesco Giuseppe De Rosa; Matteo Bassetti Journal: Infect Drug Resist Date: 2022-04-22 Impact factor: 4.177
Authors: Silvia Corcione; Tommaso Lupia; Carlo Pallotto; Daniele Roberto Giacobbe; Ilaria De Benedetto; Giacomo Stroffolini; Simone Mornese Pinna; Carlo Tascini; Matteo Bassetti; Francesco Giuseppe De Rosa Journal: Antibiotics (Basel) Date: 2022-01-02
Authors: Sara Alosaimy; Abdalhamid M Lagnf; Taylor Morrisette; Sarah C J Jorgensen; Trang D Trinh; Evan J Zasowski; Marco R Scipione; Jing J Zhao; Ryan Mynatt; Shelbye Herbin; Sorabh Dhar; Teena Chopra; James Janisse; Nicholas Rebold; Jason M Pogue; Michael J Rybak Journal: Open Forum Infect Dis Date: 2021-05-23 Impact factor: 3.835